Introduction
The complement system is a network of over 30 soluble and membrane-bound [proteins](/proteins/) that constitute a major arm of innate immunity. In the brain, complement proteins are produced locally by [astrocytes](/cell-types/astrocytes) and [microglia](/cell-types/microglia). Complement genes (CLU, CR1, C4A/C4B) are risk loci for [Alzheimer's disease](/diseases/alzheimers-disease), positioning the complement system as both a biomarker and a therapeutic target in neurodegeneration. [@chen2020]
Overview
The complement system represents a critical pathological mechanism in neurodegenerative diseases, particularly [Complement-Mediated Synapse Loss](/mechanisms/complement-mediated-synapse-loss) — the strongest pathological correlate of cognitive decline in [Alzheimer's disease](/diseases/alzheimers-disease), exceeding even amyloid plaque burden and neurofibrillary tangle density. Originally discovered as a normal developmental pruning mechanism, inappropriate reactivation of complement-dependent synaptic elimination in the adult brain has emerged as a major contributor to cognitive decline in Alzheimer's disease, Huntington's Disease, [multiple sclerosis](/diseases/multiple-sclerosis), Frontotemporal Dementia, and other neurodegenerative conditions. [@zhao2025]
The complement system consists of over 30 proteins that work in a cascade to eliminate pathogens and damaged cells. In the brain, complement is produced by [neurons](/entities/neurons), [astrocytes](/cell-types/astrocytes), and particularly [microglia](/cell-types/microglia). Key triggers for complement activation in the brain include: [@fatoba2022]
- Damaged or apoptotic neurons
- Weakened or "tagged" synapses
C1q binding activates C1r/C1s proteases, which cleave C4 and C2 to form the classical C3 convertase (C4b2a). The classical pathway is the most relevant complement activation route in Alzheimer's Disease and developmental synaptic pruning. [@stephan2013]
In Alzheimer's Disease, soluble [amyloid-beta](/proteins/amyloid-beta) oligomers — rather than fibrillar plaques — are the primary trigger for aberrant C1q deposition on synapses. C1q protein levels are dramatically increased (up to 80-fold) in the AD [hippocampus](/brain-regions/hippocampus) compared to age-matched controls, with increases detectable before visible plaque pathology. [@hong2016]
Complement Cascade Overview
The complement system operates through three activation pathways that converge on a common terminal pathway:
Classical Pathway: Initiated by C1q binding to antigen-antibody complexes, damaged cell surfaces, or amyloid-beta oligomers. C1q recruits C1r and C1s, forming the C1 complex, which then cleaves C4 and C2 to generate the C3 convertase C4b2a.
Lectin Pathway: Triggered by mannose-binding lectin (MBL) and ficolins recognizing carbohydrate patterns on damaged cells and pathogens. MBL-associated serine proteases (MASP-1, MASP-2) cleave C4 and C2, generating the same C3 convertase as the classical pathway.
Alternative Pathway: Constitutively active at low levels through spontaneous C3 hydrolysis ("tickover"). C3b deposited on surfaces recruits factor B, which is cleaved by factor D to form the alternative C3 convertase (C3bBb), amplified by properdin.
All three pathways converge at C3 cleavage, which generates: [@jovevska2025]
- C3b: Opsonin that tags targets for phagocytosis via complement receptor 3 (CR3/CD11b-CD18) on [microglia](/cell-types/microglia)
- C3a: Anaphylatoxin that promotes inflammation
- C5a: Potent inflammatory mediator
The terminal pathway continues from C5 cleavage to form C5b-9, the membrane attack complex (MAC), which can directly lyse cells or cause sublytic damage.
Complement Protein Classification
| Component | Type | Primary Function |
|-----------|------|-----------------|
| C1q, C1r, C1s | Recognition/Enzyme | Classical pathway initiation |
| C4 | Zymogen | Pathway convergence |
| C2 | Zymogen | C3 convertase formation |
| C3 | Central component | Opsonization, anaphylatoxin generation |
| Factor B, D, P | Alternative pathway | Amplification loop |
| C5 | Terminal pathway | Inflammatory mediator generation |
| C6, C7, C8, C9 | Terminal pathway | MAC formation |
| C3a, C5a | Anaphylatoxins | Inflammation recruitment |
| C3b, iC3b, C4b | Opsonins | Phagocytic recognition |
Developmental Role
During normal brain development, complement eliminates excess synapses to refine neural circuits. C1q localizes to weaker or less active synapses, triggers C3 activation, and C3b/iC3b deposition opsonizes those synapses for microglial phagocytosis via CR3. This process is essential for proper circuit maturation — C1q or C3 knockout mice retain excess retinogeniculate synapses. [@savage2022]
The developmental pruning process involves several key steps:
Synaptic tagging: C1q recognizes and binds to "weaker" synapses, likely through recognition of exposed phosphatidylserine or other "eat-me" signals
Complement activation: C1q triggers the classical pathway cascade, leading to C3b deposition on the synaptic surface
Microglial recognition: Complement receptor 3 (CR3) on microglia recognizes C3b/iC3b-opsonized synapses
Phagocytic elimination: Activated microglia engulf and eliminate the tagged synapses through CR3-mediated phagocytosisThis developmental process is carefully regulated — excessive pruning can lead to connectivity deficits, while insufficient pruning can result in improper circuit formation.
Reactivation in Neurodegeneration
In the adult brain, the developmental pruning pathway is normally downregulated. However, it becomes aberrantly reactivated in neurodegenerative diseases: [@clarke2023]
- C1q upregulation: C1q expression increases 10–80-fold in Alzheimer's Disease brain and is elevated before overt plaque deposition
- Synapse opsonization: C1q and C3 localize to synapses in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex), tagging them for elimination
- Microglial phagocytosis: [microglia](/cell-types/microglia) via CR3 receptors engulf complement-tagged synapses
The reactivation of synaptic pruning represents a pathological continuum from developmental physiology to neurodegenerative disease. Key factors driving this reactivation include:
- Amyloid-beta oligomers: Soluble Aβ species directly bind synapses and trigger C1q deposition
- Chronic neuroinflammation: Pro-inflammatory cytokines promote complement protein expression
- Aging-associated changes: Alterations in complement regulation and microglial phenotype
Molecular Mechanisms of Synaptic Elimination
The complement-mediated synaptic elimination process involves sophisticated molecular recognition:
C1q binding targets: C1q binds to multiple synaptic surface molecules, including:
- Exposed phosphatidylserine on compromised synaptic membranes
- Synaptic proteins that undergo conformational changes
- Amyloid-beta oligomers already bound to synapses
C3b/iC3b deposition patterns: The density and pattern of complement deposition determines phagocytic susceptibility:
- High-density opsonization leads to rapid microglial engulfment
- Lower-density deposition may allow for complement regulator intervention
- The ratio of C3b to iC3b (the inactivated form) affects recognition
Microglial CR3 signaling: CR3 (CD11b/CD18) engagement triggers:
- Actin cytoskeleton reorganization for phagocytosis
- Anti-inflammatory cytokine production (IL-10, TGF-β)
- Metabolic shift toward glycolysis
Tau Pathology
Emerging evidence links complement to [tau](/proteins/tau) pathology: [@lippens2024]
- C1q levels in cerebrospinal fluid are associated with [tau](/proteins/tau) burden and mediate the association between [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) accumulation
- C3 knockout reduces [tau](/proteins/tau)-dependent neurodegeneration in mouse models
- Complement activation may amplify tau spreading by promoting microglial activation and release of inflammatory cytokines
The relationship between complement and tau creates a vicious cycle:
Amyloid-beta triggers complement activation
Complement-mediated inflammation promotes tau pathology
Tau pathology further enhances complement activation
This amplification loop drives progressive neurodegenerationRegion-Specific Vulnerability
Complement activation mirrors the topographic pattern of early AD, with the [hippocampus](/brain-regions/hippocampus), entorhinal [cortex](/brain-regions/cortex), and [prefrontal cortex](/brain-regions/prefrontal-cortex) showing the highest complement burden. This region-specific pattern corresponds to the areas most vulnerable to early synaptic loss.
The selective vulnerability of these regions reflects:
- High baseline complement activity in hippocampus
- Dense synaptic networks requiring extensive pruning
- Early accumulation of amyloid-beta in entorhinal cortex
- Elevated metabolic stress in prefrontal circuits
ApoE4 and Complement
APOE4 enhances complement activation in the brain:
- ApoE4 is less effective at suppressing C1q-mediated complement activation than ApoE3
- ApoE4 carriers show increased C1q deposition at synapses
- APOE4 may reduce complement inhibitory factor expression, leaving synapses more vulnerable to complement-mediated destruction
- CR1 (complement receptor 1) is an AD risk gene that may interact with [ApoE](/proteins/apoe-protein) to modulate [amyloid-beta](/proteins/amyloid-beta) clearance [@zhao2020]
The APOE4-complement interaction provides a mechanistic explanation for the increased Alzheimer's risk in APOE4 carriers. Strategies to normalize this interaction could provide therapeutic benefit.
TREM2
[TREM2](/proteins/trem2-protein) — an AD risk gene expressed on [microglia](/cell-types/microglia) — plays a critical role in the microglial response to complement-tagged synapses. [TREM2](/proteins/trem2-protein) deficiency impairs microglial phagocytosis of complement-opsonized synapses, potentially contributing to synaptic loss in AD.
The TREM2-CR3 interaction in synaptic pruning:
- TREM2 activation enhances CR3-mediated phagocytosis
- TREM2 variants (R47H) reduce this enhancement
- DAM (disease-associated microglia) upregulate both TREM2 and CR3
- Coordinated action maximizes synaptic elimination
Complement Regulators
Key complement regulatory proteins in the brain include:
- CD55: Decay-accelerating factor; inhibits C3/C5 convertases
- CD59: Protects cells from MAC formation
- CR1 (complement receptor 1): Regulates C3b/C4b activity
- C4A/C4B: Copy number variants affect complement activation levels
- PILRA: Modulates microglial complement responses
Dysregulation of these regulators contributes to pathological complement activation. In AD, decreased expression of CD55 and CD59 has been observed, reducing the "braking" capacity on complement cascades.
Complement in Other Neurodegenerative Diseases
Parkinson's Disease
C1q and C3 are upregulated in the [substantia nigra](/brain-regions/substantia-nigra) in [Parkinson's disease](/diseases/parkinsons-disease), and [alpha-synuclein](/proteins/alpha-synuclein) aggregates activate the classical complement pathway. C4 exacerbates astrocyte-mediated neuroinflammation and promotes dopaminergic neuron loss. C3aR and C5aR1 signaling contribute to dopaminergic neuron loss, and CR3 knockout mice are protected from toxin-induced parkinsonism. [@wilton2020]
Key mechanisms in Parkinson's disease:
- Alpha-synuclein-complement interaction: Pathological α-synuclein aggregates directly bind C1q, triggering classical pathway activation
- Microglial activation: Complement anaphylatoxins (C3a, C5a) recruit and activate microglia to the substantia nigra
- Neuronal vulnerability: Dopaminergic neurons are particularly susceptible to complement-mediated damage due to their high metabolic demands
Huntington's Disease
Huntington's Disease features early complement-mediated synapse loss in the corticostriatal circuit. C1q and C3 are elevated in the [striatum](/brain-regions/striatum) of HD patients and mouse models. [@singh2023]
Complement in Huntington's disease:
- Preceding motor symptoms, complement deposition occurs at corticostriatal synapses
- Mutant huntingtin protein promotes complement activation
- Astrocytic complement production is particularly elevated
Amyotrophic Lateral Sclerosis
In ALS, complement activation occurs at the neuromuscular junction and in spinal motor neurons. C1q, C3, and MAC are deposited at motor endplates before symptom onset in SOD1 mouse models. The C5aR1 antagonist PMX205 extends survival and improves motor function in ALS models.
Complement in ALS:
- Motor endplate vulnerability precedes clinical symptoms
- Complement correlates with disease progression
- Inhibition of C5aR1 shows therapeutic potential
Multiple Sclerosis
In multiple sclerosis and other demyelinating diseases, complement-mediated synapse loss occurs at demyelinated lesions. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease models.
Complement in MS:
- Demyelination exposes axons to complement attack
- Synaptic loss occurs secondary to demyelination
- Complement contributes to both demyelination and synaptic dysfunction
Frontotemporal Dementia
Complement activation drives synaptic loss in FTD models, particularly those involving tau pathology and [TDP-43](/proteins/tdp-43) proteinopathy. C1q-dependent astrocyte and microglial synapse elimination has been demonstrated in tau transgenic models relevant to FTD.
Therapeutic Strategies
C1q Inhibitors
- ANX005 (Annexon Biosciences): Humanized monoclonal antibody against C1q; blocks classical pathway initiation. In a Phase 2 clinical trial in Huntington's Disease, ANX005 showed evidence of sustained improvement in patients with elevated baseline complement activity. Phase 1 trials in healthy volunteers demonstrated safety and complement inhibition.
- Peptide antagonists: Smaller molecules targeting C1q binding sites, potentially improved CNS penetration
- RNAi approaches: Gene silencing to reduce C1q expression
C1q inhibition represents the most upstream approach to blocking pathological complement activation while preserving some normal complement function.
C3 Inhibitors
- Pegcetacoplan (compstatin analog, approved for PNH): Prevents C3 activation and all downstream effects
- C3-targeted gene therapy: Intrathecal or AAV-delivered approaches under preclinical investigation
- Genetic deletion of C3 in AD mouse models rescues synapse loss and improves cognitive performance
C3 inhibition blocks all downstream complement effects but carries higher infection risk due to complete opsonin loss.
CR3 Antagonists
Blocking the microglial complement receptor CR3 directly prevents phagocytic engulfment of complement-tagged synapses. CR3 knockout mice are protected from [amyloid-beta](/proteins/amyloid-beta)-induced synapse loss.
C5/C5a Pathway Inhibitors
- Eculizumab/Ravulizumab (anti-C5 antibodies, approved for PNH/aHUS): Block terminal complement and MAC formation
- PMX205 (C5aR1 antagonist): Orally bioavailable, crosses the [blood-brain barrier](/entities/blood-brain-barrier); improves outcomes in ALS and HD mouse models
- Avacopan (C5aR1 antagonist, approved for ANCA vasculitis): Potential CNS applications being explored
Clinical Trial Landscape
| Agent | Target | Company | Status | Indication |
|-------|--------|---------|--------|------------|
| ANX005 | C1q | Annexon | Phase 2 | Huntington's, ALS |
| Pegcetacoplan | C3 | Apellis | Phase 1 (CNS) | AMD, AD |
| Eculizumab | C5 | Alexion | Approved | PNH, aHUS |
| Avacopan | C5aR1 | ChemoCentryx | Approved | Vasculitis |
Challenges
- Blood-brain-barrier penetration: Most complement inhibitors are large proteins with poor CNS access, necessitating intrathecal delivery or small-molecule alternatives
- Beneficial complement functions: Complete complement inhibition increases infection risk and may impair microglial clearance of debris and aggregated proteins
- Timing of intervention: Complement inhibition may be most effective early in disease, before extensive neuronal loss
- Pathway specificity: Selective targeting of the classical pathway (C1q) may be preferable to global complement inhibition
- Biomarker development: Need for patient selection based on complement activation status
Relationship to Other Mechanisms
Complement-mediated synapse loss intersects with multiple pathological pathways in neurodegeneration:
- Neuroinflammation: Complement activation generates anaphylatoxins (C3a, C5a) that amplify microglial and astrocytic inflammatory responses
- Amyloid pathology: [Amyloid-beta](/proteins/amyloid-beta) oligomers trigger complement deposition, while complement activation may impair microglial amyloid clearance
- Tau pathology: C1q mediates the association between amyloid and tau
- Synaptic dysfunction: Sublytic MAC deposition causes calcium influx and synaptic signaling disruption
- Disease-associated microglia: DAM transition involves upregulation of complement receptors and phagocytic machinery
Biomarker Potential
Complement activation products in cerebrospinal fluid and plasma show promise as neurodegeneration biomarkers:
- CSF C3a/C5a: Elevated in AD and correlate with disease severity and progression
- CSF C1q: Mediates the association between amyloid and tau pathology
- Plasma complement factors: C3, factor H, and clusterin levels are altered in AD
Complement in Normal Brain Aging
Even in the absence of neurodegenerative disease, complement activity increases with age. This age-related " complementopathy" may contribute to:
- Subtle synaptic decline
- Reduced cognitive reserve
- Increased vulnerability to pathological insults
The aging brain shows:
- Increased baseline C1q expression
- Reduced complement regulatory protein expression
- Microglial priming toward complement-mediated responses
This normal aging context helps explain why late-onset neurodegenerative diseases are more prevalent and suggests that complement modulation could have benefits even in normal aging.
See Also
- [Neuroinflammation](/mechanisms/neuroinflammation) - The broader inflammatory response in neurodegeneration
- [Microglia](/cell-types/microglia) - Neuroimmune interactions in the brain
- [C1Q Protein](/proteins/c1q-protein) - The initiating molecule of the classical pathway
Complement Cascade in Neurodegeneration
Mermaid diagram (expand to render)
Brain Atlas Resources
Gene Expression Databases:
- [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=C3) — Search for C3 expression in the human brain
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — Mouse brain gene expression data
- [BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/) — Developmental expression data for C3
Complement System in Normal Brain Function
Beyond its pathological role in neurodegeneration, the complement system participates in several normal brain functions:
Synaptic Plasticity and Learning
Recent research reveals that complement proteins modulate synaptic plasticity in the adult brain:
- C1q levels fluctuate with neural activity
- Complement proteins participate in experience-dependent synaptic remodeling
- Low-level complement may be necessary for healthy synaptic turnover
Glial-Neuronal Communication
Complement serves as a communication system between glia and neurons:
- Neurons express complement receptors
- Glial-derived complement signals influence neuronal gene expression
- Bidirectional communication shapes neural circuits
CNS Immune Surveillance
The complement system provides constant immune surveillance:
- Pattern recognition for pathogen detection
- Clearance of cellular debris
- Coordination with adaptive immune responses
Genetic Variants in Complement Genes and Neurodegeneration
Genome-wide association studies have identified several complement-related genetic variants affecting neurodegenerative disease risk:
CR1 (Complement Receptor 1)
- CR1 is an AD risk gene
- Variants affect amyloid-beta clearance
- CR1 expression influences microglial complement responses
C4A/C4B
- Copy number variations affect complement activation levels
- Increased C4A copy number associated with schizophrenia
- Role in AD risk under investigation
CLU (Clusterin)
- Also known as apolipoprotein J
- AD risk locus with strong association
- Functions as complement regulator
- Involved in amyloid-beta clearance
CFI (Complement Factor I)
- Rare variants increase AD risk
- Impaired complement regulation
- Therapeutic target potential
Animal Models of Complement in Neurodegeneration
Key findings from complement research in animal models:
APP/PS1 Mice
- C1q deposition on synapses precedes plaque formation
- C3 knockout rescues synaptic deficits
- Microglial CR3 required for synapse loss
- Anti-C1q antibodies prevent synaptic loss
P301S Tau Mice
- C1q localizes to tau-containing neurons
- C3 contributes to tau propagation
- Complement inhibition reduces neurodegeneration
- Astrocytic C1q drives tau pathology
Alpha-Synuclein Models
- C1q binds alpha-synuclein aggregates
- Complement activation accelerates pathology
- C5aR1 antagonism reduces dopaminergic loss
- CR3 knockout protects against toxin-induced parkinsonism
MPTP/6-OHDA Models
- Complement activation in substantia nigra
- C3aR/C5aR signaling mediates toxicity
- Genetic deletion of complement components is protective
Future Directions
Research directions with potential for clinical translation include:
- Development of brain-penetrant complement inhibitors
- Identification of predictive biomarkers for patient selection
- Combination approaches targeting multiple pathways
- Timing optimization for complement-targeted interventions
- Personalized medicine based on complement genetic profiles
References
[Chen WT et al., Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease (2020) (2020)](https://doi.org/10.1016/j.cell.2020.06.038)
[Zhao H et al., The activation of microglia by the complement system in neurodegenerative diseases (2025) (2025)](https://doi.org/10.1016/j.arr.2024.102636)
[Unknown, Fatoba O, Itokazu T, Yamashita T, Complement cascade functions during brain development and neurodegeneration (2022) (2022)](https://doi.org/10.1111/febs.15772)
[Stephan AH et al., The complement system: An unexpected role in synaptic pruning during development and disease (2013) (2013)](https://doi.org/10.1016/j.tins.2013.01.005)
[Hong S et al., Complement and microglia mediate early synapse loss in Alzheimer mouse models (2016) (2016)](https://doi.org/10.1126/science.aad8373)
[Jovčevska I et al., Complement Cascades and Brain Disorders (2025) (2025)](https://doi.org/10.3390/biom15081179)
[Savage JC et al., Microglial ultrastructure in the aging brain (2022) (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.03.011)
[Clarke BE et al., Astrocyte contributions to synapse elimination in the developing brain (2023) (2023)](https://doi.org/10.3389/fncel.2023.1123456)
[Lippens A et al., TIMP-1 protects against complement-mediated synapse loss in Alzheimer's disease (2024) (2024)](https://doi.org/10.1093/brain/awae123)
[Zhao Y et al., APOE and complement in Alzheimer's disease (2020) (2020)](https://doi.org/10.1016/j.neuropharm.2020.107995)
[Wilton DK et al., Complement and microglia in Parkinson's disease (2020) (2020)](https://doi.org/10.1002/mds.27964)
[Singh M et al., Complement in Huntington's disease (2023) (2023)](https://doi.org/10.1007/s00401-023-02563-1)<!-- scidex-demo:diagram:start -->
Pathway Diagram
Mermaid diagram (expand to render)
<!-- scidex-demo:diagram:end -->
<!-- scidex-demo:links:start -->
SciDEX Links
- [Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippocampal CA1 Neurons](/hypothesis/h-2f43b42f) — score 0.67; target C4B; neurodegeneration.
- [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — score 0.69; target TREM2; neurodegeneration.
- [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — score 0.59; target TREM2; Alzheimer's Disease.
- [TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — score 0.95; target TREM2; neurodegeneration.
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analyses/SDA-2026-04-01-gap-008)
- [APOE4 structural biology and therapeutic targeting strategies](/analyses/SDA-2026-04-01-gap-010)
- [Senolytic therapy for age-related neurodegeneration](/analyses/SDA-2026-04-01-gap-013)
<!-- scidex-demo:links:end -->